StockData
Beta Bionics, Inc. logo

Beta Bionics, Inc. (BBNX) income statement

BBNXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 11/304% below fair value
$14.33−0.39 (-2.65%)

Close on Nov 18, 2026Market cap $779.08MP/E –Yield –

Beta Bionics, Inc. income statement

Ratios

Latest available, balances at Sep 30, 2026

Profitability, TTM

Gross margin
58.6%
Operating margin
-72.7%
Net margin
-65.3%
Return on equity, FY2025
-346.5%

Financial strength

Current ratio
8.92
Debt to equity
–
Debt to assets
–
Cash to current liabilities
248.4%

Valuation

P/E ratio
–
Price to sales
6.12
Price to book
1.94
Dividend yield
–

See a number that looks wrong?